Procainamide (PA), a cardioactive drug, inhibited the degradation of both cocaine (COC) and cocaethylene (CE) when either was incubated in human liver homogenates for 3 h at 37~ PA appeared to enhance the formation of CE when COC and ethanol (ETOH) were incubated together in liver homogenate. These observations are clinically significant because cardiotoxicity is common after COC abuse and because PA may be administered to individuals who use COC alone and with ETOH.
Introduction
male (head trauma in motor-vehicle accident); 22-yearoold male (hypothermia); 39-year-old female (arteriosclerotic heart disease); and 46-year-old male (arteriosclerotic heart disease). There was no known history of drug abuse or liver disease in any decedent.
Approximately 100 g of each liver was rinsed with water and then homogenized with 1000 mL of phosphate buffer (0.1 tool/L, pH 7.4) in a Waring blender (Baxter Diagnostics, Scientific Products Division, McGaw Park, IL). Each homogenate was strained through a colander, and an aliquot was subjected to comprehensive drug screening (7) . No drugs were detected in any homogenate. Equal volumes (950 mL) of each homogenate were pooled and frozen (-20~ until use.
Cocaine (COC) and cocaethylene (CE), a pharmacologically significant transesterification product formed when COC and ethanol (ETOH) are used concurrently (1, 2) , have become of increasing interest to toxicologists.
Recently this laboratory reported that the cardioactive drug procainamide (PA) at a high pharmacological concentration of 42.5 pmol/L inhibits the degradation of COC by 42.7% and that of CE by 47.2% following a 2-h incubation of either compound in human serum at 37~ (3). Both COC and CE concentrations studied were similar to those commonly noted after ingestion of COC and ETOH together (4) . Although it is well established that plasma cholinesterase catalyzes the metabolic debenzoylation of COC and its homologues (5,6), PA did not suppress the activity of butyrylcholinesterase in serum in that study, even when PA concentrations were increased to 425 IJmol/L.
The present study investigates the effect of PA on the hepatic metabolic degradation of COC and CE in vitro and its effect on the hepatic formation of CE from COC and ETOH.
Experimental

Human liver homogenate
Human liver was obtained at autopsy from the following five decedents: 29-year-old male (gunshot to the head); 66-year-old 
Drug solutions
Stock solutions of COC hydmchloride (Merck & Co., Rahway, N J) and CE base (Sigma Chemical Co., St. Louis, MO) were prepared in phosphate buffer (0.1 tool/L, pH 7.4) at concentrations of 330,000 and 315,000 nmol/L, respectively. PA hydrochloride (Sigma) was prepared at concentrations of 8500 and 42501Jmol/L in phosphate buffer (0.1 tool/L, pH 7.4). ETOH was diluted to 32% (w/v) (6960 mmol/L) in water.
Study of COC and CE hepatic degradation
Three milliliters of COC stock solution was added to approximately 300 mL of pooled liver homogenate to yield a concentration of about 3300 nmol/L. Similarly, CE stock solution was added to liver homogenate to yield a concentration of approximately 3150 nmol/L. Sufficient volumes of PA stock solutions were added to 19 mL of each supplemented homogenate to yield PA concentrations of 42.5, 85, and 340 ]~mol/L in the COC-supplemented liver homogenate and 170 and 340 IJmollL in the CE-supplemented homogenate. Immediately after preparation, 4 mL of each sample was withdrawn, treated with 100 pL of saturated sodium fluoride to inhibit hepatic esterases, and frozen (-20~ until the time of analysis, which was within 2-3 days in each case. These samples provided zero-time (baseline) values. The remaining homogenates were then incubated in culture tubes in a waterbath at 37~ for 3 h, after which 4 mL of each was withdrawn, treated with sodium fluoride, and frozen until analysis.
Each concentration (both zero-and 3-h) was studied in singlet except for the controls (COC alone and CE alone), which were studied in duplicate and for which the results were averaged.
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Study of CE formation
Pooled liver homogenate (100 mL) was placed into each of two 250-mL Erlenmeyer flasks. To each flask were added 1 mL of COC stock solution and 1 mL of the ETOH solution to yield concentrations of approximately 3300 nmol/L for COC and 69.6 mmol/L of ETOH. To one flask was added 1 mL of PA stock solution to yield a PA concentration of 42.5 pmol/L To the other flask was added 1 mL of phosphate buffer (0.1 mol/L, pH 7.4) to maintain volume equivalence between the two flasks. Immediately after supplementation of each liver homogenate, 4 mL was withdrawn 4.0, and 6.0 h. Each sample was treated with sodium fluoride and frozen until the time of analysis, which was within 2-3 days. Each time point was studied once.
Analysis of COC and CE
The concentrations of COC and CE were measured in liver homogenates by high-pressure liquid chromatography (8) using reference calibrators of concentration 660 nmol/L for COC and 630 nmol/L for CE, prepared in the same pooled liver homogenate treated with sodium fluoride as preservative (25 pL/mL of homogenate). To each study sample was added n-propylbenzoylecgonine (Alltech-Applied Science Labs, State College, PA) as internal standard. After buffering I mL of each sample to pH 9.3, each was extracted with hexane/isoamyl alcohol (98:2, v/v) and back-extracted into 200 pL of HCI (0.1 mol/L), an aliquot of which was subjected to high-pressure liquid chromatography on a C-8 column maintained at 48~ Effluents were monitored at 235nM, and concentrations were calculated using peak-height ratios (COC or CE/internal standard) in the unknowns relative to those of the reference calibrators.
All concentrations from an experiment were measured in the same analytical run. The published within-run coefficients of variation for the analytical method are less than 5% at the concentrations studied (8) . The method has been used reliably by the author for more than 5 years.
Calculation of percent degradation of COC and CE
The percent degradation of COC and CE was calculated as follows: 100% (0-time concentration -3-h concentration)/(0-time concentration)
Results
PA substantially inhibited the hepatic degradation of COC (Table I) and CE (Table It) . In addition, PA appeared to enhance the formation of CE from COC and ETOH in liver homogenate (Tables III and IV, Figure 1) . 
Discussion
This laboratory previously reported that PA at a high pharmacological concentration of 42.5 ]amol/L inhibits the metabolic degradation of COC by 42.7% and that of CE by 47.2% in human serum within 2 h without suppression of butyrylcholinesterase activity (3) . Although the present study suggests that the inhibitory effect of PA may be less in liver (COC alone, 27% degradation; COC + PA, 10.4%-15.6%) ( Table I ) (CE alone, 7.0%; CE + PA, 0.5%-1.5%) (Table II) , it should be recalled that the hepatic enzymatic activity was substantially diluted during preparation of the liver homogenate, which used 10 mL of phosphate buffer per gram of liver.
The hepatic degradation of CE alone (no PA) at 3 h (7.0%) (Table II) appeared to be much less than that of COC alone (no PA) (27.0%) ( Table I ). This is consistent with the longer half-life (slower metabolism) of CE relative to that of COC (9) .
In the presence of ETOH and without PA, the degradation of COC (at least after 3 h of incubation and beyond) appeared to be enhanced somewhat: 50.2% at 3 h with ETOH (Table III) versus 27.0% at 3 h without ETOH (Table I) . This is likely due to the fact that, in addition to ongoing hepatic metabolism of COC, this compound was also being transestefifled with ETOH.
PA appeared to enhance the formation of CE from COC and ETOH (Table III versus Table IV , Figure 1 ). This may be due to the inhibition of COC degradation by PA, which permitted more COC to be converted to CE while PA inhibited the degradation of CE itself at the same time.
Although PA did not suppress butyrylcholinesterase activity in serum even at PA concentrations as high as 425 Iamol/L in the earlier study (3) , it is conceivable that it does inhibit hepatic carboxylesterases, one of which is known to catabolize COC to benzoylecgonine and (in the presence of ETOH) to convert it to CE (10), and another of which catabolizes COC to ecgonine methyl ester (11) . However, the activity of these enzymes was not measured in this study.
Inhibition of the hepatic degradation of COC and CE by PA as well as enhancement of the formation of CE by PA has important clinical implications because cardiotoxicity is a relatively common effect of COC usage (12) , and PA could conceivably be administered to COC-using patients. Based upon the preliminary evidence provided in this study, this could potentiate the effects of COC and CE.
